Compare Summit Therapeutics Inc (SMMT) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Uranium Energy Corp — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while Uranium Energy Corp trades at $9.59 (market cap $4.65B). The key difference: Summit Therapeutics Inc is far larger — about 2.3× Uranium Energy Corp's market cap. Which is the better fit depends on your goals.
| SMMT | UEC | |
|---|---|---|
Market Cap | $10.48B | $4.65B |
Sector | Health | Energy |
52-Week High | $29.32 | $20.14 |
52-Week Low | $13.05 | $8.00 |
Enterprise Value | $9.90B | $4.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Uranium Energy Corp (UEC) trades at $9.40, up 1.29% today, amid bearish technical signals and challenging fundamentals. The stock shows negative profitability with a net income margin of -513.24% and has missed earnings estimates in two of the last three quarters. Recent news highlights operational pressures and strategic positioning in the uranium sector, with analyst sentiment remaining largely positive despite financial headwinds.
The outlook for UEC hinges on execution of its in-situ recovery ramp-up and uranium sales timing. Investment opportunity lies in its debt-free balance sheet and $794 million liquidity, but risks include persistent losses, high valuation multiples, and reliance on uranium price recovery. Wall Street maintains a buy-heavy consensus, suggesting long-term potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
